Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Alan Meds vs GoodRx

Two GLP-1 deals, scored on the same six factors. Alan Meds lands a Value Score of 90, GoodRx a 74. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Alan Meds

#7 · Grade A · Best Value

Est. first month

$99/mo

Save ~93% vs brand-name
Get this deal Full Alan Meds review →
VS

GoodRx

#149 · Grade C+ · Watch List

Est. first month

From $149/mo (brand Foundayo)

Get this deal Full GoodRx review →

The verdict

Better value: Alan Meds

Alan Meds takes it on Value Score, 90 to 74 an est. $99/mo first month, with no teaser step-up baked in. GoodRx isn't out of it: Shoppers who want self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealAlan MedsGoodRx
Value Score90 (A)74 (C+)
Est. first month$99/moFrom $149/mo (brand Foundayo)
Save vs brand-name~93%
Semaglutide$99/moNot disclosed
Tirzepatide$145/moFrom $299/mo (brand Zepbound)
Both moleculesYesNo
PricingFlat — no step-upWatch
CoverageAll 50 statesAll 50 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

95
Lowest Real Price
82
Alan Meds: 95. GoodRx: 82.
85
No Teaser-Rate Bait
60
Alan Meds: 85. GoodRx: 60.
98
Nationwide Availability
96
Alan Meds: 98. GoodRx: 96.
94
Both Molecules
62
Alan Meds: 94. GoodRx: 62.
82
Easy Cancellation
58
Alan Meds: 82. GoodRx: 58.
72
Reputation
84
Alan Meds: 72. GoodRx: 84.

Alan Meds

Double-digit semaglutide ($99) and a $145 tirzepatide, both nationwide, with an oral route for the needle-shy.

Why it's a deal

  • $99 flat semaglutide and a low $145 tirzepatide
  • Available in all 50 states
  • Offers an oral/sublingual route

The fine print

  • Not LegitScript-certified — do your own pharmacy diligence
  • Newer operator with a thin public track record

GoodRx

GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

Why it's a deal

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

The fine print

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
Get the Alan Meds deal Get the GoodRx deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Alan Meds is ranked on the Alan Meds alternatives board, and the same list for the other side is on alternatives to GoodRx.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.